These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31594790)

  • 1. N-Terminal Modification of the Tetrapeptide Arg-Leu-Tyr-Glu, a Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Antagonist, Improves Antitumor Activity by Increasing its Stability against Serum Peptidases.
    Yun JA; Kim J; Baek YY; Park W; Park M; Kim S; Kim T; Choi S; Jeoung D; Lee H; Won MH; Kim JY; Ha KS; Kwon YG; Kim YM
    Mol Pharmacol; 2019 Dec; 96(6):692-701. PubMed ID: 31594790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
    Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
    Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human plasminogen-derived N-acetyl-Arg-Leu-Tyr-Glu antagonizes VEGFR-2 to prevent blood-retinal barrier breakdown in diabetic mice.
    Park W; Kim J; Choi S; Kim T; Park M; Kim S; You JC; Kim JH; Ha KS; Lee JH; Kwon YG; Kim YM
    Biomed Pharmacother; 2021 Feb; 134():111110. PubMed ID: 33338749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration.
    Koo HC; Baek YY; Choi JS; Kim YM; Sung B; Kim MJ; Kim JG; You JC
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tetrapeptide Arg-Leu-Tyr-Glu inhibits VEGF-induced angiogenesis.
    Baek YY; Lee DK; So JH; Kim CH; Jeoung D; Lee H; Choe J; Won MH; Ha KS; Kwon YG; Kim YM
    Biochem Biophys Res Commun; 2015 Aug; 463(4):532-7. PubMed ID: 26051280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arg-Leu-Tyr-Glu Suppresses Retinal Endothelial Permeability and Choroidal Neovascularization by Inhibiting the VEGF Receptor 2 Signaling Pathway.
    Park W; Baek YY; Kim J; Jo DH; Choi S; Kim JH; Kim T; Kim S; Park M; Kim JY; Won MH; Ha KS; Kim JH; Kwon YG; Kim YM
    Biomol Ther (Seoul); 2019 Sep; 27(5):474-483. PubMed ID: 31042676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical Administration of a Novel Acetylated Tetrapeptide Suppresses Vascular Permeability and Immune Responses and Alleviates Atopic Dermatitis in a Murine Model.
    Sung B; Baek YY; Kim YM; You JC
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis.
    Kim DG; Jin Y; Jin J; Yang H; Joo KM; Lee WS; Shim SR; Kim SW; Yoo J; Lee SH; Yoo JS; Nam DH
    MAbs; 2015; 7(6):1195-204. PubMed ID: 26325365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
    Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
    Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
    Liu W; Zhang J; Yao X; Jiang C; Ni P; Cheng L; Liu J; Ni S; Chen Q; Li Q; Zhou K; Wang G; Zhou F
    Cancer Sci; 2018 Oct; 109(10):3294-3304. PubMed ID: 30151975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
    Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
    Gao J; Hu H; Wang X
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
    Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
    Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy.
    Shen G; Li Y; Du T; Shi G; Dai L; Chen X; Zheng R; Li W; Su X; Zhang S; Wei Y; Yang S; Deng H
    Neoplasma; 2012; 59(5):486-93. PubMed ID: 22668017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice.
    Zhou K; Zhang JW; Wang QZ; Liu WY; Liu JL; Yao L; Cai MM; Ni SY; Cai QY; Wang GJ; Zhou F
    Acta Pharmacol Sin; 2019 Apr; 40(4):556-562. PubMed ID: 29977004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.